Skip to main content
. 2020 Jan 9;105(11):2584–2591. doi: 10.3324/haematol.2019.227215

Figure 3.

Figure 3.

MEN1309/OBT076 combined with the BCL2 inhibitor venetoclax and the anti-CD20 monoclonal antibody rituximab exerts cytotoxicity downregulating MCL1, cleaving PARP and upregulating CD20 protein. Two cell lines were exposed to MEN1309/OBT076 (1nM), venetoclax (100 nM), rituximab (20 g/mL) or the combination of the agents for 72 hours. -tubulin was used as a loading control. Figure is representative of two independent experiments.